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ABSTRACT
Background: Because bronchial inflammation was recognized as a basic component of bronchial asthma,
the strategy for asthma management has changed in the last two decades. In Japan there are few clinico-
epidemiological reports of changes in the management of bronchial asthma in actual practice.
In this study, we analyzed practical asthma management in Japan, and examined changes in the prevalence of
asthma medication and relation between these changes and the level of asthma control and management.
Methods: From 1998 to 2002, questionnaires on asthma control, asthma related emergent episodes and sat-
isfaction in daily life. Questionnaires were distributed to adult asthmatic patients. Questionnaires about the pa-
tients’ profiles and medication were also given to the patients’ doctors.
Results: The total number of patient responders was approximately 2500―3300 per year. The rate of peak
flow meter (PEFM) use was under approximately only 40% and plateaued from 2000 to 2002. The percentage
of inhaled corticosteroid use and leukotriene receptor antagonist use increased, from 62.0%, 27.2% to 77.4%,
40.6% respectively. Indicators for asthma control, including presence of attacks and sleep disturbance, were
significantly improved. Limited to PEFM users, there was an improvement hospitalization, ambulance use or
ED visits and in satisfaction in daily life based on a Quality of Life (QOL) indicator.
Conclusions: These results indicate that the prevalence of anti-inflammatory agents, including inhaled corti-
costeroids and leukotriene receptor antagonist, was associated with an adequate improvement in asthma con-
trol in clinical practice. In asthma management in clinical practice, prevalence of PEFM may play an important
role in the improvement of asthma related emergent episodes or QOL.
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INTRODUCTION
The morbidity of bronchial asthma in Japan is report-
edly about 3% in adults and 5% in children, a situation
that clearly has been increasing.1 Many studies have
attributed this to an increase in exposure to allergens
derived from animals and microorganisms associated
with changes in the living environment and life-
styles. 2,3 The management and treatment of bron-
chial asthma has changed due to the fact that in re-
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Table 1 Summary of the atending institutes and numbers of questionnaires each year
20022001200019991998year
60008000610063006000total numbers of prepared questionnaires
25933293306932243347total numbers of answered questionnaires
  27  32  32  33  32numbers of institutions (large-sized hospitals: beds＞＝200)
16262171190020091940numbers of answered questionnaires
  24  24  30  34  35numbers of institutions (smal/middle-sized hospitals: beds＜200)
 602 650 668 689 780numbers of answered questionnaires
  27  44  47  86  86numbers of institutions (clinics: no beds)
 365 448 501 526 627numbers of answered questionnaires
cent years the disease has been recognized as
chronic airway inflammation caused by inflammatory
cells including mainly eosinophils and lympho-
cytes. 4,5 Guidelines for bronchial asthma in many
countries6,7 recommend anti-inflammatory treatments
using inhaled corticosteroids ICSs ( inhaled corti-
costeroid) as the main treatment. Some studies have
recently reported that the use of inhaled steroids in
patients with initial symptoms of bronchial asthma, or
what is generally termed early intervention, improved
subsequent respiratory function.8
The mainstays of the managementtreatment of
bronchial asthma include , ( i ) the evaluation and
monitoring of asthma, (ii) the management of factors
influencing the severity of asthma, (iii) drug therapy,
and ( iv ) patient education . Because the manage-
menttreatment of asthma in adults generally re-
quires a long-term period, quality of life (QOL), lead-
ing to normal activity levels, must be taken into con-
sideration . However , medical providers are some-
times neither able to meet the patient’s needs in the
actual clinical setting, nor provide patients with ade-
quate education . Given these problems associated
with the treatmentmanagement of bronchial asthma,
which have been minimally discussed and analyzed
in Japan, the Niigata Asthma Treatment Study Group
conducted a questionnaire survey among adult pa-
tients with bronchial asthma who visited medical in-
stitutions in Niigata Prefecture in September and Oc-
tober starting in 1998. The attending physicians of
these patients were also been included in the survey.
To clarify the changes in the prevalence of asthma
medication and the relation between these changes
and the level of asthma control and management, this
paper reports on the analysis of the results of succes-
sive changes obtained from surveys conducted from
1998 to 2002 in Niigata Prefecture, Japan.
METHODS
This questionnaire-based investigation was per-
formed over five consecutive years, from 1998 to 2002
in Niigata Prefecture, Japan, under the Ethical Princi-
ples for Medical Research Involving Human Subjects,
DECLARATION OF HELSINKI. The numbers and
the kinds of involved institutions each year are shown
in Table 1. The numbers of prepared and answered
questionnaires are also indicated in Table 1. The con-
tents of the questionnaire are shown in Table 2 (origi-
nally in Japanese) . To avoid annual influence , the
questionnaire was presented annually in Japanese .
However, two questions, smoking status and the last
onset of episodes associated with asthma death (Ta-
ble 2, Question 3, 6−8) were added later (from 2000
and from 2001). And to exclude seasonal influences,
questionnaires during each of the five years were car-
ried out over 2 months from September to October.
The subjects were recruited from a group of patients
with adult bronchial asthma (sixteen years and up-
ward) who regularly (usually once or twice per 4
weeks) visited the participating institutes for asthma
management. On their regular visit during the study
period, they were asked by their physician to attend
this study. The recruited patients were asked to com-
plete a questionnaire by themselves (Table 2). There-
fore, the understanding of the used technical terms
such as “attack” or “unconsciousness” in the ques-
tionnaire (Table 2) was dependent on each patient
self-understanding.
For an evaluation of asthma control during each
year, patients were asked about the mean peak flow
value and the presence of asthma attacks during the
two weeks prior to answering the questionnaire. The
patients were also asked about their asthma condition
during the one-year period prior to answering the
questionnaire by choosing 1 of 3 answers: “ few at-
tacks,” “seasonal attacks” and “frequent attacks.” The
questionnaires asked about asthma-related symptoms
including coughing and sputum in the morning and
at night , and about sleep disturbance in the two
weeks prior to answering the questionnaire.
The questionnaires also inquired about asthma re-
lated emergent episodes including ambulance use ,
emergency department visits and hospitalization, and
related events with fatal asthma attacks including un-
consciousness or respirator management and anti-
inflammatory-agent induced asthma attacks AIA (as-
pirin induced asthma). The subjects were asked to
answer “yes” or “no” to the following five questions;
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Table 2 Contents of the questionnaires used for asthmatic patients in this study (Original questionnaires were described in 
Japanese.)
Age: years old Gender: male/female
Question 1
When were you diagnosed as bronchial asthma?
 Year:  Month:  Day:
Question 2
1) Do you use a peak-flow meter?
 (Yes, No)
2) Please describe the mean value of your peak-flow meter during the last 2 weeks.
 morning:    night:
Question 3
Choose in folowings
1) How did your asthma atacks appear during the last 12 months?
(frequent atacks, seasonal atacks, few atacks)
2) How many times were your asthma atacks during the last 2 weeks?
(5―7/week, 3―4/week, 1―2/week, absent)
3) What kinds of the degree was your asthma atacks during the last 2 weeks?
(impossible to move, impossible to lie down, possible to lie down, strider, dyspnea on exertion)
4) Have you ever been hospitalized due to asthma?
(yes, no)
5) Have you ever been taken by ambulance or visited an emergency room due to an atack?
(yes, no)
6) Have you ever had a respirator due to an asthma atack?
(yes, no)
7) Have you ever been unconscious due to an asthma atack?
(yes, no)
8) Have you ever had an atack induced by anti-inflammatory drugs including painkilers, antipyretics, or cold medicine?
Question 4
How was your asthma condition during the last 2 weeks?
(very good, fairly good, mediocre, slightly bad, bad)
Question 5
Choose your symptoms during the last 2 weeks in folowings
1) in the morning
(cough, sputa, chest tightness, stridor, dyspnea, absent)
2) at night
(cough, sputa, chest tightness, stridor, dyspnea, absent)
3) sleep disturbance
(impossible to fal asleep sometimes due to dyspnea, impossible to have a good sleep due to dyspnea, waking up in 
the night due to chest oppression, absent)
Question 6
Do you satisfy in daily life?
(very satisfide, fairly satisfied, mediocre, slightly unsatisfied, unsatisfied)
“Have you ever been hospitalized due to asthma?”,
“Have you ever been taken by ambulance or visited
an emergency room due to an attack?” “Have you
ever used a respirator due to an asthma attack? ” ,
“Have you ever been unconscious due to an asthma
attack?” and “Have you ever had an attack induced by
anti-inflammatory drugs including painkillers, antipy-
retics, or cold medicine?” Therefore, aside from ques-
tions about asthma control , the experiences were
asked in Question 3, 4―8 (Table 2).
To evaluate problems concerned with asthma man-
agement and treatment considering QOL related with
normal activity levels, the questionnaires asked about
satisfaction in patients’ daily life that was used as a
measure of QOL. The subjects answered by choosing
1 of 5 answers: “very satisfied,” “fairly satisfied,” “me-
diocre,” “slightly unsatisfied,” and “unsatisfied.”
Concurrent with the patients’ completing the ques-
tionnaire, their physicians were asked to answer the
details of current treatment mainly as controller, the
type of asthma (atopic or nonatopic) in accordance
with the elevation of serum total IgE or the significant
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Table 3 Adult bronchial asthma severity assessment com-
mitee’ sstandards of the Japanese Society of Alergology
degree of symptom
frequency
D (D1/D2)CBA
moderatemoderateseveresevere5―7/week
mildmoderatemoderatesevere3―4/week
mildmildmoderatesevere1―2/week
A: impossible to move due to dypnea, B: impossible to lie down 
due to dyspnea, C: possible to lie down even with dyspnea, D1: 
stridor alone, D2: chest tightness alone
detection of specific IgE for allergens, and the sever-
ity of asthma in accordance with the adult bronchial
asthma severity assessment committee’s standards of
the Japanese Society of Allergology. As shown in Ta-
ble 3, the severity is, in principle, classified according
to the combination of frequency and degree of at-
tacks during the worst consecutive prior 4 weeks .
However , in cases of administration of corticoster-
oids , total dosages of corticosteroids including in-
haled corticosteroids were used to decide the sever-
ity independent of the situation of asthma attacks. A
case was decided as severe when more than 10 mg
day was used and moderate from 5 mgday to
10 mgday, respectively, calculated as prednisolone.
The results are expressed as arithmetic means
(±SD) for continuous variables. The differences be-
tween dichotomous variables were analyzed by chi-
square test. A Kruskal-Wallis test was used to test for
the equality of distributions of continuous variables.
The pairwise year-to-year comparison was performed
by chi-square test and Wilcoxon’s rank sum test with
Bonferroni’s correction for the significance level. All
statistical analyses were performed with the statistical
software BMDP 3S (BMDP, Los Angeles, CA, USA)
and Statxact (Cytel Software Co., Cambridge, MA,
USA).
RESULTS
CHANGES IN PATIENT BACKGROUND
Changes in patient background are summarized in
Table 4. The number of patients who responded was
approximately 2500―3300, aged between 54―56 years
on average, with a mean duration of disease of ap-
proximately 11―16 years (Table 4-a). Percentage of fe-
males increased and in 2002 females were apparently
dominant. Over the survey years here was a signifi-
cant increase in the cases of atopic disease type and
moderate cases. Although peak flow meter (PEFM)
was used in about 31% of the patients in 1998 and the
rate significantly increased by about 10% over the
next two years, there was no further increase in 2001
and 2002 (Table 4-b). The later results indicate that a
limitation could exist in the promotion of PEFM.
CHANGES IN DRUG MEDICATION
The results concerning changes of drug medication
as controller were shown in Table 5. The proportion
of patients using ICSs and LTRAs (leukotriene recep-
tor antagonists) significantly increased from 62.0% ,
27.2% to 77.4%, 40.6% respectively, over four years .
These results indicate that an anti-inflammatory strat-
egy for asthma treatment is becoming widely ac-
cepted in actual clinical management. The proportion
of oral steroid use which is indicative of steroid-
dependent asthma decreased successively from 18.8%
to 10.4% . During this period , the rate of oral
sustained-released theophylline OSRT ( oral
sustained-released theophylline) use was more than
70% , but the proportion showed a significant de-
crease.
CHANGES IN %PEF (PERCENTAGES FOR THE
PREDICTED PEAK FLOW VALUE) AND PRES-
ENCE OF ASTHMA ATTACKS DURING THE TWO
WEEKS PRIOR TO ANSWERING THE QUES-
TIONNAIRE
The data are summarized in Table 6-a. Changes in
%PEF in the morning and at night gradually in-
creased although the percentages of PEFM users
were not more than approximately 40%. There was a
significant decrease in the proportion of patients who
experienced asthma attacks during the two weeks
prior to answering the questionnaire. These results
suggest that the control of bronchial asthma im-
proved over the years from 1998 to 2002.
CHANGES IN ASTHMA ATTACKS DURING THE
ONE-YEAR PERIOD PRIOR TO ANSWERING
THE QUESTIONNAIRE
To clarify asthma control in the long term, asthma at-
tacks over the 1 year prior to answering the question-
naire were classified as described in the methods sec-
tion. The percentage of patients answering, “frequent
attacks” and “ few attacks” in 1998 was 18.9% and
31.9%, respectively. The former decreased and the lat-
ter increased every year, and reached 8.7% and 46.2%
in 2002, respectively Table 6-b),( indicating that the
prevention of asthma attacks in the long term also im-
proved.
CHANGES IN ASTHMA-RELATED SYMPTOMS
AND SLEEP DISTURBANCE DURING THE TWO
WEEKS PRIOR TO ANSWERING THE QUES-
TIONNAIRE
Because sleep disturbance and asthma-related symp-
toms in the morning and at night are likely to appear
in asthmatics, we examined the proportion of patients
who had such symptoms. The rate of symptomatic re-
lated patients in the morning and night significantly
decreased from 55.8%, 42.8% to 40.8%, 25.8% respec-
tively and sleep disturbance also significantly im-
proved from 33.1% to 11.8% (Table 6-c). These results
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Table 4-a Patient background I
duration (mean＋/−SD)age (mean＋/−SD)gender: % (N: male/female)year
11.5＋/−12.354.4＋/−17.650.0/50.0 (1670/1673)1998
10.9＋/−11.953.9＋/−17.651.0/49.0 (1643/1581)1999
15.9＋/−18.455.8＋/−16.749.1/50.9 (1508/1561)2000
12.1＋/−12.8*, #, $55.3＋/−17.5#49.3/50.7 (1580/1623)2001
12.7＋/−13.7¥56.0＋/−16.8¥46.2/53.8 (1198/1394)*, ###2002
*p＜0.05 vs. 1998, #p＜0.05 vs. 1999, ###p＜0.001 vs. 1999, $p＜0.05 vs. 2000, $p＜0.05 vs. 2001, ¥p＜0.05 vs. 2002 by means 
of Bonferoni’ scorection for multiple chi-square tests.
Table 4-b Patient background I
number of PEF user (%)severity: % (N: mild/moderate/severe)type: % (N: atopic/nonatopic)year
1032 (30.8)48.8/41.1/10.1 (1542/1299/318)68.1/31.9 (2197/1029)1998
1123 (34.8)***45.3/44.6/10.1 (1435/1415/321)*71.6/28.4 (2247/892)**1999
1238 (40.3)***, ###44.5/46.1/9.4 (1307/1354/277)***69.1/30.9 (2005/898)#2000
1277 (39.1)***, ###41.3/49.4/9.3 (1319/1576/297)***, ###, $72.5/27.5 (2277/863)***, $$$2001
1020 (39.3)***, ###40.1/49.8/10.1 (1003/1248/253)***, ###, $$72.6/27.4 (1800/681)***, $$$2002
*p＜0.05 vs. 1998, **p＜0.01 vs. 1998, ***p＜0.001 vs. 1998, #p＜0.05 vs. 1999, ###p＜0.001 vs. 1999, $p＜0.05 vs. 2000, $$p
＜0.01 vs. 2000, $$$p＜0.001 vs. 2000
Table 5 Changes in drug medication in asthmatic patient
Rate of each drug use (%)
year
OSRT†LTRA†OCS†ICS†
79.627.218.862.01998
79.333.714.866.51999
75.734.112.371.42000
72.837.212.073.52001
71.940.610.477.42002
† :p＜0.001 by means of Cochran’ slinear trend tests. ICS: in-
haled corticosteroid, OCS: oral corticosteroid, LTRA: leukotriene 
receptor antagohist, OSRT: oral susrained-released theophyline
also indicated an improvement in asthma control.
CHANGES IN ASTHMA RELATED EMERGENT
EPISODES INCLUDING AMBULANCE USE ,
EMERGENCY DEPARTMENT VISITS AND HOS-
PITALIZATION, AND EPISODES RELATED WITH
NEAR FATAL ASTHMA ATTACKS INCLUDING
ATTACKS WITH UNCONSCIOUSNESS , RESPI-
RATOR MANAGEMENT AND AIA ATTACKS
The treatment of asthma also aims at avoiding
asthma-related emergent episodes, especially asthma
deaths in addition to the prevention of asthma attacks
and maintenance of normal lung function. The pro-
portions of patients who had visited an emergency de-
partment (ED) or who had used an ambulance did
not significantly decrease when compared to 1998
data. The proportion of patients who had been hospi-
talized due to asthma attacks showed no significant
decrease when compared with 1998 data (Table 7-a).
Moreover, there were no consistent tendencies in the
proportion of patients who had experienced near fatal
asthma attacks directly associated with asthma-
related death, such as attacks with unconsciousness,
respirator management and AIA (Table 7-b). Consid-
ering that there were no further increases of PEFM
use in 2001 and 2002 (Table 4-b), the comparisons be-
tween PEFM users and non-users were performed.
Although there were no significant changes of attacks
with unconsciousness , respirator management and
AIA in both groups, significant decreases of hospitali-
zation in 2002 and of ambulance use or ED visits in
2001 were found only in PEFM users (Tables 7-c, d).
CHANGES IN SATISFACTION OF DAILY LIFE
Another target of asthma treatment is to allow pa-
tients to gain normal activity levels. In this context,
satisfaction of daily life in the questionnaires is one of
the most important factors of QOL indicators . In
1998, responses of “very satisfied” and “fairly satis-
fied” were recorded in 14.8% and 56.9% of respon-
dents respectively. Responses of “mediocre”, “slightly
unsatisfied” or “unsatisfied” were cited in 15.7%, 9.1%
and 1.4% respectively. There were no significant per-
centage changes when compared with the previous
year (Table 8-a). The same analyses were performed
as the analysis of the changes in asthma related
emergent episodes and episodes related with near fa-
tal asthma attacks . The satisfaction of daily life in
2001 was significantly improved not in regard to
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Table 6-a Changes in peak flow values and presence of asthma atacks during the two weeks prior to answering the question-
naire
PA (%)%PEF (night, mean＋/−SD)%PEF (morning, mean＋/−SD)year
36.479.6＋/−20.076.4＋/−20.91998
31.7***81.1＋/−19.276.0＋/−19.91999
27.7***81.6＋/−20.179.6＋/−20.12000
24.4***, ###, $81.5＋/−21.379.2＋/−21.2*2001
22.5***, ###, $$82.6＋/−19.280.8＋/−19.22002
*p＜0.05 vs. 1998, ***p＜0.001 vs. 1998, ###p＜0.001 vs. 1999, $p＜0.05 vs. 2000, $$p＜0.01 vs. 2000 by means of Bonferoni’ s
 corection for chi-square tests. % PEF: percentage of predicted peak flow value, PA: presence of asthma atacks during the two weeks 
prior to answering the questionnaire
Table 6-b Changes in asthma atacks during the one year 
period prior to answering the questionnaire
seasonal/few/frequent/not answered (%)year
1117/1067/631/532 (33.4/31.9/18.9/15.9)1998
1086/1127/544/467 (33.7/35.0/16.9/14.5)1999
1033/1202/401/433 (33.7/39.2/13.1/14.1)*, #2000
1021/1417/351/480 (31.2/43.3/10.7/14.7)*2001
 771/1197/225/399 (29.7/46.2/8.7/15.4)*, #2002
*p ＜ 0.05 vs. 1998, #p ＜ 0.05 vs. 1999 by means of Bonferoni’ s
corection for Kruskal-Walis tests.
PEFM non-users but in PEFM users (Tables 8-b, c).
DISCUSSION
This study analyzed the changes in patients with
bronchial asthma in the Niigata Prefecture, Japan us-
ing data from surveys conducted from 1998 to 2002.
Participating patients totaled more than 2500 each
year from many different medical institutions in vari-
ous parts of Niigata Prefecture, Japan (Table 1). One
of important problems of this study was the quality of
the used questionnaires, i.e. the used questionnaire
was not validated, because at the beginning of this
study there were no validated questionnaires to
evaluate for asthma management of each asthmatic
patient in practice. It was suitable, however, that the
analytical results can reflect to some degree an actual
situation of medication and management for bron-
chial asthma, because the contents in the question-
naire (Table 2) were often used for the management
of asthma in clinical practice.
Although the changes in the degree of severity
were likely to be worse in this study, it was thought
to be an apparent increase. The classification of se-
verity used in this study was based not only on the
frequency and degree of symptoms(Table 3) but also
on the total doses of corticosteroid required for
asthma control, as mentioned in the method section.
Therefore , we think that an introduction or an in-
creased dose of inhaled corticosteroids resulted in
the shift to a worse severity classification. Another
important factor is the spread of self-management us-
ing PEFM . Sudre et al. reported that self-
management by PEFM significantly reduced hospi-
talization of patients with asthmatic attacks and re-
sulted in a decrease in medical expenses.9 Consider-
ing this, influence of PEFM use can be excluded after
2000 because no significant changes were found .
However , the changes in hospitalization are not
thought to be associated directly with those in the
use of PEFM. This will be discussed in later. Note the
rate of PEFM use plateaued and was under about 40%
in 2000, 2001 and 2002. Although asthma manage-
ment by PEFM is one of the important evaluation
methods for pulmonary function in several guide-
lines,6,7 this indicates that there was a certain limita-
tion of this management using PEFM and that an-
other method such as spirometry might be consid-
ered. In practice, measurement of FEV1 by pulmo-
nary function test would play a same important role
as PEFM.
The survey results showed a gradual improvement
in the control of bronchial asthma, as is clearly shown
by the presence of asthma attacks , situations of
asthma attacks during the two weeks and the one
year prior to answering the questionnaire, the asthma
related symptoms and sleep disturbance . This im-
provement is likely to be associated with the preva-
lence in anti-inflammatory agents such as ICSs and
LTRAs, although the same patients had not been sur-
veyed consecutively throughout the study period .
The important point in treatment analysis was the in-
crease in ICS use and the decrease in oral corticoster-
oid OCS (oral corticosteroid) use. This is because
guidelines for asthmatic treatment steadily spread
among physicians in the Niigata Prefecture , Japan
and these physicians began to use ICSs in early
stages. In addition, the introduction of fluticasone has
allowed (available on 1999 in Japan) the reduction in
and withdrawal OCSs in patients with severe asthma
and led to an overall reduction in OCS use . This
study revealed a remarkably high rate of OSRT use,
which has been traditionally used in Japan, but a sig-
nificant decrease in it occurred. These results also in-
dicated that the strategy for asthma treatment includ-
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Table 6-c Changes in asthma-related symptoms and sleep disturbance during the two weeks prior to answering the question-
naire
sleep disturbance (%)ARS (night: %)ARS (morning: %)year
33.142.858.41998
30.639.7***55.4**1999
29.4*39.3***54.2***, ###, $$$2000
14.6***, ###, $$$28.7***, ###, $$$42.4***, ###, $$$2001
11.8***, ###, $$$, ¥25.8***, ###, $$$40.8***, ###, $$$2002
*p＜0.05 vs. 1998, **p＜0.01 vs. 1998, ***p＜0.001 vs. 1998, ###p＜0.001 vs. 1999, $$$p＜0.001 vs. 2000, ¥p＜0.05 vs. 2001 
by means of Bonferoni’ scorection for multiple chi-square tests. ARS: asthma related symptoms during the two weeks prior to answering 
the questionnalre
Table 7-a Changes in hospitalization, ambulance use or 
ED visits
ambulance use or ED visits (%)hospitalization (%)year
40.947.01998
39.645.91999
37.445.72000
37.143.32001
39.143.12002
No significant diferences were observed between any of 
groups by means of Bonferoni’ scorection for multiple chi-
square tests. ED: emergency department
ing ICSs and LTRAs was accepted by many physi-
cians. However, considering the high rate in OSRT
use, this medicine added to ICSs, which was reported
to be more effective than doubling dosage of
ICSs,10,11 may play an important role in the improve-
ment of asthma control in this study . However , a
long-acting inhaled beta2 agonist has recently been
available in Japan and may partly replace theophylline
in future.
One of the important aspects of the management of
bronchial asthma is asthma-related emergent episode
(Tables 7-a,7-b). These episodes can be closely re-
lated not only with overall medical costs12 but also
with in part asthma-related death.13 In fact, asthma-
related death has decreased with approximately 4,000
patients dying from asthma annually in Japan.14 The
number is larger than other advanced countries and
urges effective measures to be taken to reduce
deaths caused by asthma. Unfortunately , Table 7-a
did not indicate a significant improvement in the man-
agement of asthma related with emergency episodes
in asthma attacks with all surveyed patients. There
were almost no changes in the frequency of near-fatal
asthmatic conditions associated with serious attacks
involving unconsciousness and management with a
respirator , and there were no significant changes
either in the frequency of AIA that is also known as
one of near fatal asthma attacks (Table 7-b). These
findings appear to be contradictory both to improve-
ments in the management of asthma shown in this
study and to previous reports.15,16 This was mainly
why only experiences but not onset time of these epi-
sodes were required in the questionnaire used. Pa-
tients in the same medical institutions may have been
removed every year and the same patients may have
been included to some extent in the survey. It might
take a longer time to detect a significant reduction in
asthma-related emergent episodes. It was conclusive
that the questionnaire we performed was inadequate
to evaluate the changes in asthma associated emer-
gent events in the present study design. However ,
considering the plateau prevalence of PEFM (Ta-
ble 4-b) and the decreased rates of hospitalization and
of ambulance use or ED visits in the PEFM users (
Table 7-c), PEFM use may play an important role in
the improvement of these points.
Like other chronic diseases, the evaluation of QOL
in the management of asthmatic patients has been
stressed in recent years. The evaluation of QOL is
performed using questionnaires containing questions
about physical and psychological conditions to evalu-
ate overall function and life conditions with respect to
the patient’s lifestyle. The Nottingham Health Profile
method and SF-36 Health Status Question-
naire17 method have been used in recent years. To
evaluate more patients, the degree in satisfaction of
daily life was used as a plausible measure for QOL in
this study. There were no significant improvements
in satisfaction in daily life. Apart from the validation of
this question, as previously reported that ICSs and
LTRAs can contribute QOL improvement,18,19 there
are several possible explanations for our results. One
is that this question was too simple to reflect QOL.
Another is that satisfaction in daily life responses
were directed not to QOL associated with asthma but
to QOL independent asthma. In sum, the method to
evaluate the changes in QOL in asthmatic patients in
this study was thought to be inadequate. However, as
the same point was discussed in the analysis of the
changes in asthma related emergent episodes, a par-
tial improvement of satisfaction of daily life in PEFM
users (Table 8-b) may also indicate a potent contribu-
tion to the improvement of QOL.
In summary , questionnaire surveys conducted
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Table 7-b Changes in atacks with unconsciousness, respirator management and AIA atacks
AIA atacks (%)respirator management (%)atacks with unconsciousness (%)year
8.635.866.781998
8.876.347.321999
8.736.356.812000
8.195.576.552001
8.956.366.912002
No significant diferences were observed between any of groups by means of Bonferoni’ scorection for multiple chi-square tests. AIA: 
aspirin induced asthma
Table 7-c Changes in hospitalization, ambulance use or ED visits in PEFM users and PEFM non-users
ambulance use or ED visits (%)hospitalization (%)
year
PEFM non-usersPEFM usersPEFM non-usersPEFM users
37.951.840.562.61998
38.449.940.058.81999
36.546.137.559.92000
35.845.8**37.356.82001
37.548.838.654.5*2002
*p＜0.05 vs. 1998, **p＜0.01 vs. 1998 by means of Bonferoni’ scorection for multiple chi-square tests. ED: emergency department, 
PEFM: peak flow meter
Table 7-d Changes in atacks with unconsciousness, respirator management and AIA atacks in PEFM users and PEFM non-
users
AIA atacks (%)respirator management (%)atacks with unconsciousness (%)
year
PEFM non-usersPEFM usersPEFM non-usersPEFM usersPEFM non-usersPEFM users
6.8212.214.46 8.724.7110.611998
7.2712.345.22 9.135.1111.551999
7.9111.885.56 8.225.76 9.692000
6.4011.864.44 8.474.92 9.872001
7.3512.165.0810.095.5610.542002
No significant diferences were observed between any of groups by means of Bonferoni’ scorection for multiple chi-square tests. AIA: 
aspirin induced asthma, PEFM: peak flow meter
Table 8-a Changes in satisfaction in daily life in al pa-
tients
very satisfied/fairly satisfied/mediocre/
slightly unsatisfied/unsatisfied (%)
year
494/1906/524/306/47 (15.7/56.9/15.7/9.1/1.4)1998
436/1866/485/319/45 (13.5/57.9/15.0/9.9/1.4)1999
403/1738/476/306/57 (13.1/56.6/15.5/10.0/1.9)2000
479/1916/492/246/45 (14.6/58.6/15.1/7.5/1.4)2001
423/1415/431/191/29 (16.3/54.6/16.6/7.4/1.1)2002
No significant diferences were observed between any of 
groups by means of Bonferoni’ scorection for Kruskal-Walis 
tests
Table 8-b Changes in satisfaction in daily life in PEFM us-
ers
very satisfied/fairly satisfied/mediocre/
slightly unsatisfied/unsatisfied (%)
year
149/591/147/108/17 (14.7/58.4/14.5/10.7/1.7)1998
151/676/145/117/19 (13.6/61.1/13.1/10.6/1.7)1999
172/702/180/135/29 (14.1/57.6/14.8/11.1/2.4)2000
195/758/181/96/17 (15.6/60.8/14.5/7.7/1.4)#, $2001
173/561/173/83/7 (17.4/56.3/17.4/8.3/0.7)2002
#p＜ 0.05 vs. 1999, $p＜ 0.05 vs. 2000 by means of Bonfer-
roni’ scorection for Kruskal-Walis tests, PEFM: peak flow meter
from 1998 to 2002 among adult patients with bron-
chial asthma and their attending physicians in the Nii-
gata Prefecture Japan were analyzed on a successive
basis . Not only control of asthma attacks but also
asthma-related symptoms and sleep disturbance were
improved , with the consequence of spread use of
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Table 8-c Changes in satisfaction in daily life in PEFM 
non-users
very satisfied/fairly satisfied/mediocre/
slightly unsatisfied/unsatisfied (%)
year
299/1123/322/163/26 (15.5/58.1/16.7/8.4/1.3)1998
233/974/287/171/21 (13.8/57.8/17.0/10.1/1.2)1999
183/812/299/136/22 (13.2/58.8/16.6/9.8/1.6)2000
229/876/249/114/24 (15.3/58.7/16.7/7.6/1.6)2001
193/623/207/79/17 (17.2/55.7/18.5/7.1/1.5)2002
No significant diferences were observed between any of 
groups by means of Bonferoni’ scorection for Kruskal-Walis 
tests, peak flow meter
ICSs and LTRAs. There was a certain limitation in the
popularization of PEFM, indicating that other meth-
ods, such as measurement of FEV1.0, to evaluate pul-
monary function may be required in asthma manage-
ment . No improvement was observed concerning
both inhibition of asthma-related emergent episodes
and QOL in all surveyed patients, indicating that the
questionnaire used this time was inadequate to evalu-
ate these issues in this study design. However, the
limited but significant improvement in asthma related
emergent episodes and in satisfaction of daily life in
PEFM users of the patients may indicate that the
prevalence of PEFM may play an important role in
these points. Given the current status, it is necessary
to continue and improve these questionnaire surveys
and perform more precise analyses to aim at higher-
quality medicine.
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